PE20120055A1 - (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa - Google Patents
(1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasaInfo
- Publication number
- PE20120055A1 PE20120055A1 PE2011001441A PE2011001441A PE20120055A1 PE 20120055 A1 PE20120055 A1 PE 20120055A1 PE 2011001441 A PE2011001441 A PE 2011001441A PE 2011001441 A PE2011001441 A PE 2011001441A PE 20120055 A1 PE20120055 A1 PE 20120055A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- phenyl
- cyclopropylmetoxy
- halogen
- benzoic acid
- Prior art date
Links
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 229940052296 esters of benzoic acid for local anesthesia Drugs 0.000 title 1
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 229950010713 carmoterol Drugs 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE (1-FENIL-2-PIRIDIN-4-IL)ETIL ESTERES DEL ACIDO BENZOICO DE FORMULA (I) COMO (-) ENANTIOMERO DONDE n ES 0 O 1; R1 Y R2 SON CADA UNO ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, OR3 O HNSO2R4, EN DONDE R3 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO O CICLOALQUILO(C3-C7); R4 ES ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON HALOGENO. SON COMPUESTOS PREFERIDOS: 1-(S)-(3-CICLOPROPILMETOXI-4-DIFLUOROMETOXI-FENIL)-2-(3,5-DICLORO-PIRIDIN-4-IL)-ETIL ESTER DEL ACIDO 3-CICLOPROPILMETOXI-4-METANOSULFONILAMINO-BENZOICO; 1-(S)-(3-CICLOPROPILMETOXI-4-DIFLUOROMETOXI-FENIL)-2-(3,5-DICLORO-1-OXI-PIRIDIN-4-IL)-ETIL ESTER DEL ACIDO 3-CICLOPROPILMETOXI-4-METANOSULFONILAMINO-BENZOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE ADEMAS CONTIENE FORMOTEROL O CARMOTEROL. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA FOSFODIESTERASA 4 (PDE4) SIENDO UTILES EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09001660A EP2216327A1 (en) | 2009-02-06 | 2009-02-06 | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120055A1 true PE20120055A1 (es) | 2012-02-16 |
Family
ID=40674203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001441A PE20120055A1 (es) | 2009-02-06 | 2010-02-04 | (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US8440834B2 (es) |
| EP (2) | EP2216327A1 (es) |
| JP (2) | JP5612610B2 (es) |
| KR (1) | KR101337728B1 (es) |
| CN (1) | CN102317262B (es) |
| AR (1) | AR075243A1 (es) |
| AU (1) | AU2010211274B2 (es) |
| BR (1) | BRPI1005695A8 (es) |
| CA (1) | CA2751494C (es) |
| CL (1) | CL2011001876A1 (es) |
| CO (1) | CO6400217A2 (es) |
| CY (1) | CY1113764T1 (es) |
| EA (1) | EA019113B1 (es) |
| ES (1) | ES2395528T3 (es) |
| GE (1) | GEP20135919B (es) |
| HR (1) | HRP20121004T1 (es) |
| IL (1) | IL214446A (es) |
| JO (1) | JO2761B1 (es) |
| MA (1) | MA33105B1 (es) |
| ME (1) | ME02325B (es) |
| MX (1) | MX2011007857A (es) |
| MY (1) | MY152048A (es) |
| NZ (1) | NZ594413A (es) |
| PE (1) | PE20120055A1 (es) |
| PL (1) | PL2393782T3 (es) |
| PT (1) | PT2393782E (es) |
| RS (1) | RS52605B (es) |
| SG (1) | SG173208A1 (es) |
| SI (1) | SI2393782T1 (es) |
| TN (1) | TN2011000346A1 (es) |
| TW (1) | TWI459945B (es) |
| UA (1) | UA102574C2 (es) |
| WO (1) | WO2010089107A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| CA2807406C (en) | 2010-08-03 | 2018-12-11 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| SI2600830T1 (en) * | 2010-08-03 | 2018-05-31 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising a phosphodiesterase inhibitor |
| EP2718267B1 (en) | 2011-06-06 | 2016-08-10 | Chiesi Farmaceutici S.p.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| EP2760838B1 (en) | 2011-09-26 | 2017-05-10 | Chiesi Farmaceutici S.p.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| CN103889972A (zh) * | 2011-10-21 | 2014-06-25 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
| AR089232A1 (es) * | 2011-12-16 | 2014-08-06 | Chiesi Farma Spa | Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia |
| IN2014DN10239A (es) | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| AR093796A1 (es) * | 2012-12-05 | 2015-06-24 | Chiesi Farm Spa | Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa |
| KR20150091061A (ko) | 2012-12-05 | 2015-08-07 | 키에시 파르마슈티시 엣스. 피. 에이. | Pde4-억제제로서 페닐에틸피리딘 유도체 |
| HK1212988A1 (zh) | 2012-12-05 | 2016-07-22 | 奇斯药制品公司 | 作为pde-4抑制剂的苯基乙基吡啶衍生物 |
| WO2014086852A1 (en) | 2012-12-05 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Phenylethylpyridine derivatives as pde4-inhibitors |
| US9427376B2 (en) | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| JP6458957B2 (ja) * | 2013-10-22 | 2019-01-30 | チエシ ファルマスティスィ エス．ピー．エー． | Ｐｄｅ４阻害剤の製造方法 |
| AR098621A1 (es) | 2013-12-05 | 2016-06-01 | Chiesi Farm Spa | Derivados de heteroarilo |
| HK1225384A1 (zh) | 2013-12-05 | 2017-09-08 | 奇斯药制品公司 | 用於治疗呼吸病的二苯甲基衍生物 |
| EP3152202B1 (en) * | 2014-06-04 | 2018-11-28 | Chiesi Farmaceutici S.p.A. | 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors and muscarinic m3 receptor antagonists |
| EP3152203A1 (en) * | 2014-06-04 | 2017-04-12 | Chiesi Farmaceutici S.p.A. | 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors |
| US9326976B2 (en) | 2014-06-05 | 2016-05-03 | Chiesi Farmaceutici S.P.A. | Carbamate derivatives |
| US9763924B2 (en) * | 2014-06-05 | 2017-09-19 | Chiesi Farmaceutici S.P.A. | Aminoester derivatives |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| EP3487501A1 (en) * | 2016-07-20 | 2019-05-29 | Allergan, Inc. | Methods, compositions, and compounds for treatment of dermatological and ocular conditions |
| MA51413A (fr) * | 2017-12-28 | 2021-04-28 | Chiesi Farm Spa | Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique |
| US11813360B2 (en) | 2018-07-27 | 2023-11-14 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| CN115466169B (zh) * | 2021-06-10 | 2024-03-26 | 中国医学科学院药物研究所 | 取代邻苯二酚醚类化合物及其制备方法和应用 |
| WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| JP2025514863A (ja) | 2022-04-27 | 2025-05-09 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐｄｅ４阻害剤の新規結晶形態 |
| WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
| EP4590273A1 (en) | 2022-09-22 | 2025-07-30 | Chiesi Farmaceutici S.p.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| WO2024062006A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| CN119947705A (zh) | 2022-09-22 | 2025-05-06 | 奇斯药制品公司 | 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263495B (es) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| PL178314B1 (pl) | 1993-07-02 | 2000-04-28 | Byk Gulden Lomberg Chem Fab | Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy |
| GB9412573D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| DE602007012105D1 (de) * | 2006-07-14 | 2011-03-03 | Chiesi Farma Spa | Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2070913A1 (en) | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| EP2110375A1 (en) | 2008-04-14 | 2009-10-21 | CHIESI FARMACEUTICI S.p.A. | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class |
| EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| SI2600830T1 (en) | 2010-08-03 | 2018-05-31 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising a phosphodiesterase inhibitor |
| CA2807406C (en) | 2010-08-03 | 2018-12-11 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| EP2718267B1 (en) | 2011-06-06 | 2016-08-10 | Chiesi Farmaceutici S.p.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| EP2760838B1 (en) | 2011-09-26 | 2017-05-10 | Chiesi Farmaceutici S.p.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| CN103889972A (zh) | 2011-10-21 | 2014-06-25 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
| IN2014DN10239A (es) | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| AR093796A1 (es) | 2012-12-05 | 2015-06-24 | Chiesi Farm Spa | Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa |
-
2009
- 2009-02-06 EP EP09001660A patent/EP2216327A1/en not_active Withdrawn
-
2010
- 2010-02-03 JO JO201033A patent/JO2761B1/en active
- 2010-02-04 NZ NZ594413A patent/NZ594413A/xx unknown
- 2010-02-04 TW TW099103291A patent/TWI459945B/zh active
- 2010-02-04 EP EP10704746A patent/EP2393782B1/en active Active
- 2010-02-04 RS RS20120547A patent/RS52605B/sr unknown
- 2010-02-04 MY MYPI2011003639 patent/MY152048A/en unknown
- 2010-02-04 MX MX2011007857A patent/MX2011007857A/es active IP Right Grant
- 2010-02-04 SI SI201030094T patent/SI2393782T1/sl unknown
- 2010-02-04 JP JP2011548600A patent/JP5612610B2/ja active Active
- 2010-02-04 SG SG2011056165A patent/SG173208A1/en unknown
- 2010-02-04 WO PCT/EP2010/000676 patent/WO2010089107A1/en not_active Ceased
- 2010-02-04 ES ES10704746T patent/ES2395528T3/es active Active
- 2010-02-04 UA UAA201108827A patent/UA102574C2/ru unknown
- 2010-02-04 PE PE2011001441A patent/PE20120055A1/es active IP Right Grant
- 2010-02-04 PT PT107047466T patent/PT2393782E/pt unknown
- 2010-02-04 EA EA201190099A patent/EA019113B1/ru unknown
- 2010-02-04 CA CA2751494A patent/CA2751494C/en active Active
- 2010-02-04 MA MA34150A patent/MA33105B1/fr unknown
- 2010-02-04 AU AU2010211274A patent/AU2010211274B2/en active Active
- 2010-02-04 PL PL10704746T patent/PL2393782T3/pl unknown
- 2010-02-04 GE GEAP201012324A patent/GEP20135919B/en unknown
- 2010-02-04 AR ARP100100311A patent/AR075243A1/es not_active Application Discontinuation
- 2010-02-04 CN CN201080006643.7A patent/CN102317262B/zh active Active
- 2010-02-04 KR KR1020117016842A patent/KR101337728B1/ko active Active
- 2010-02-04 BR BRPI1005695A patent/BRPI1005695A8/pt not_active Application Discontinuation
- 2010-02-04 ME MEP-2016-19A patent/ME02325B/me unknown
- 2010-02-04 HR HRP20121004AT patent/HRP20121004T1/hr unknown
- 2010-02-05 US US12/700,926 patent/US8440834B2/en active Active
-
2011
- 2011-07-13 TN TN2011000346A patent/TN2011000346A1/fr unknown
- 2011-08-04 CO CO11098671A patent/CO6400217A2/es not_active Application Discontinuation
- 2011-08-04 IL IL214446A patent/IL214446A/en active IP Right Grant
- 2011-08-04 CL CL2011001876A patent/CL2011001876A1/es unknown
-
2012
- 2012-09-14 US US13/618,346 patent/US20130012487A1/en not_active Abandoned
- 2012-12-04 CY CY20121101183T patent/CY1113764T1/el unknown
-
2013
- 2013-06-28 US US13/930,304 patent/US8648204B2/en active Active
- 2013-12-17 US US14/108,731 patent/US8859778B2/en active Active
-
2014
- 2014-09-04 JP JP2014179895A patent/JP2015038079A/ja active Pending
- 2014-09-10 US US14/482,287 patent/US9056176B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120055A1 (es) | (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa | |
| PE20130601A1 (es) | Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa | |
| CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| MX377553B (es) | Composicion farmaceutica estable y metodos de uso de la misma. | |
| EP2352497A4 (en) | COMPOSITIONS WITH DELTA-9-THC-AMINO-ACID ESTERS AND MANUFACTURING METHOD | |
| LT2596786T (lt) | Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti | |
| BR112012018386A2 (pt) | "inibidores isoindolinona de fosfatidilinositol 3-quinase" | |
| CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
| HRP20200226T1 (hr) | Inhibitor glukozilceramid sintaze | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| DK4338805T3 (da) | Eicosapentaensyreethylester til brug for at reducere risikoen for ikke-dødeligt myokardieinfarkt hos en patient i statinbehandling | |
| EA201100440A1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| WO2011133795A3 (en) | Beta-carbolines as inhibitors of haspin and dyrk kinases | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| MX378091B (es) | Composicion neuroprotectora anticolinergica y metodos. | |
| WO2010018109A3 (en) | Substituted aminotetralines | |
| PL2613798T3 (pl) | Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów | |
| CL2008003181A1 (es) | Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma. | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| EP2016187A4 (en) | COMPOSITIONS AND METHOD FOR THE ENZYMATIC TREATMENT OF LUNG DISEASES | |
| CO6351778A2 (es) | Acidos naftilaceticos | |
| AR078552A1 (es) | Derivados de feniloxadiazol como agentes inhibidores de las pgds | |
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MA34946B1 (fr) | Nouvelles benzodioxolepipérazines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |